Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVBP NASDAQ:CGON NYSE:JNJ NASDAQ:UPB NASDAQ:UPB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVBPArriVent BioPharma$33.69+0.1%$30.72$16.10▼$35.83$1.57B1.29614,581 shs436,615 shsCGONCG Oncology$75.24+2.6%$64.91$23.65▼$77.00$6.64B0.221.18 million shs1.04 million shsJNJJohnson & Johnson$257.17-0.7%$237.07$154.80▼$269.43$618.61B0.248.25 million shs6.53 million shsUPBUpstream Bio$7.53-3.6%$7.62$5.85▼$33.68$409.78M1.23631,278 shs341,716 shsUPBUpstream Bio$7.53-3.6%$7.62$5.85▼$33.68$409.78M1.23631,278 shs341,716 shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVBPArriVent BioPharma0.00%-2.83%+11.56%+32.33%+57.87%CGONCG Oncology0.00%+6.94%+30.53%+11.14%+178.25%JNJJohnson & Johnson0.00%-2.04%+7.79%+7.90%+64.78%UPBUpstream Bio0.00%+0.27%+18.03%-28.22%-35.64%UPBUpstream Bio0.00%+0.27%+18.03%-28.22%-35.64%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVBPArriVent BioPharma$33.69+0.1%$30.72$16.10▼$35.83$1.57B1.29614,581 shs436,615 shsCGONCG Oncology$75.24+2.6%$64.91$23.65▼$77.00$6.64B0.221.18 million shs1.04 million shsJNJJohnson & Johnson$257.17-0.7%$237.07$154.80▼$269.43$618.61B0.248.25 million shs6.53 million shsUPBUpstream Bio$7.53-3.6%$7.62$5.85▼$33.68$409.78M1.23631,278 shs341,716 shsUPBUpstream Bio$7.53-3.6%$7.62$5.85▼$33.68$409.78M1.23631,278 shs341,716 shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVBPArriVent BioPharma0.00%-2.83%+11.56%+32.33%+57.87%CGONCG Oncology0.00%+6.94%+30.53%+11.14%+178.25%JNJJohnson & Johnson0.00%-2.04%+7.79%+7.90%+64.78%UPBUpstream Bio0.00%+0.27%+18.03%-28.22%-35.64%UPBUpstream Bio0.00%+0.27%+18.03%-28.22%-35.64%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVBPArriVent BioPharma 2.78Moderate Buy$44.8333.08% UpsideCGONCG Oncology 2.71Moderate Buy$81.738.62% UpsideJNJJohnson & Johnson 2.74Moderate Buy$258.130.37% UpsideUPBUpstream Bio 2.43Hold$33.17340.46% UpsideUPBUpstream Bio 2.43Hold$33.17340.46% UpsideCurrent Analyst Ratings BreakdownLatest UPB, CGON, AVBP, JNJ, and UPB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/10/2026JNJJohnson & Johnson Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$254.00 ➝ $263.007/8/2026JNJJohnson & Johnson Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$283.00 ➝ $284.007/8/2026JNJJohnson & Johnson CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$285.00 ➝ $298.007/6/2026JNJJohnson & Johnson HSBCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetBuy$290.006/26/2026JNJJohnson & Johnson Johnson RiceSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$270.006/26/2026JNJJohnson & Johnson GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$266.00 ➝ $270.006/15/2026JNJJohnson & Johnson Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy (B) ➝ Buy (B-)6/12/2026UPBUpstream Bio JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOverweight ➝ Neutral$35.00 ➝ $8.006/12/2026UPBUpstream Bio JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOverweight ➝ Neutral$35.00 ➝ $8.006/3/2026UPBUpstream Bio HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$36.006/3/2026UPBUpstream Bio HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$36.00(Data available from 7/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVBPArriVent BioPharmaN/AN/AN/AN/A$7.44 per shareN/ACGONCG Oncology$4.04M1,642.62N/AN/A$9.33 per share8.06JNJJohnson & Johnson$94.19B6.57$14.13 per share18.20$33.85 per share7.60UPBUpstream Bio$2.85M143.78N/AN/A$6.29 per share1.20UPBUpstream Bio$2.85M143.78N/AN/A$6.29 per share1.20Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVBPArriVent BioPharma-$166.31M-$3.47N/AN/AN/AN/A-48.98%-45.44%8/10/2026 (Estimated)CGONCG Oncology-$160.99M-$2.33N/AN/AN/AN/A-23.33%-22.24%8/7/2026 (Estimated)JNJJohnson & Johnson$26.80B$8.6529.7320.362.5121.83%32.60%13.29%7/15/2026 (Estimated)UPBUpstream Bio-$143.44M-$2.91N/AN/AN/A-4,718.96%-43.82%-42.27%8/5/2026 (Estimated)UPBUpstream Bio-$143.44M-$2.91N/AN/AN/A-4,718.96%-43.82%-42.27%8/5/2026 (Estimated)Latest UPB, CGON, AVBP, JNJ, and UPB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2026Q2 2026CGONCG Oncology-$0.70N/AN/AN/A$0.33 millionN/A8/5/2026Q2 2026UPBUpstream Bio-$0.78N/AN/AN/A$0.43 millionN/A8/5/2026Q2 2026UPBUpstream Bio-$0.78N/AN/AN/A$0.43 millionN/A7/15/2026Q2 2026JNJJohnson & Johnson$2.85N/AN/AN/A$25.02 billionN/A5/13/2026Q1 2026UPBUpstream Bio-$0.73-$0.7470-$0.0170-$0.75$1.03 million$1.03 million5/13/2026Q1 2026UPBUpstream Bio-$0.73-$0.7470-$0.0170-$0.75$1.03 million$1.03 million5/11/2026Q1 2026AVBPArriVent BioPharma-$0.88-$0.96-$0.08-$0.96N/AN/A5/8/2026Q1 2026CGONCG Oncology-$0.58-$0.71-$0.13-$0.71$0.45 million$1.08 million4/14/2026Q1 2026JNJJohnson & Johnson$2.68$2.70+$0.02$2.14$23.60 billion$24.06 billionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAVBPArriVent BioPharmaN/AN/AN/AN/AN/ACGONCG OncologyN/AN/AN/AN/AN/AJNJJohnson & Johnson$5.362.08%+5.25%61.97%64 YearsUPBUpstream BioN/AN/AN/AN/AN/AUPBUpstream BioN/AN/AN/AN/AN/ALatest UPB, CGON, AVBP, JNJ, and UPB DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date4/14/2026JNJJohnson & Johnsonquarterly$1.342.33%5/26/20265/26/20266/9/2026(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVBPArriVent BioPharmaN/A13.9513.95CGONCG OncologyN/A31.3031.25JNJJohnson & Johnson0.461.030.77UPBUpstream BioN/A23.1423.14UPBUpstream BioN/A23.1423.14Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVBPArriVent BioPharma9.48%CGONCG Oncology26.56%JNJJohnson & Johnson69.55%UPBUpstream BioN/AUPBUpstream BioN/AInsider OwnershipCompanyInsider OwnershipAVBPArriVent BioPharma8.58%CGONCG Oncology4.80%JNJJohnson & Johnson0.16%UPBUpstream Bio16.46%UPBUpstream Bio16.46%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVBPArriVent BioPharma4046.58 million42.58 millionN/ACGONCG Oncology6188.20 million83.97 millionOptionableJNJJohnson & Johnson138,2002.41 billion2.40 billionOptionableUPBUpstream Bio3854.42 million45.46 millionN/AUPBUpstream Bio3854.42 million45.46 millionN/AUPB, CGON, AVBP, JNJ, and UPB HeadlinesRecent News About These CompaniesUpstream Bio, Inc. (NASDAQ:UPB) Given Consensus Recommendation of "Hold" by BrokeragesJuly 6, 2026 | americanbankingnews.comIs Upstream Bio, Inc. (UPB) a Rising Biotech Opportunity After New Analyst Coverage?June 25, 2026 | insidermonkey.com10 small-cap U.S. healthcare stocks with the weakest momentum gradesJune 24, 2026 | seekingalpha.comIs Upstream Bio, Inc. (UPB) the Best Low Priced Stocks to Get Rich in 2026?June 23, 2026 | insidermonkey.comUpstream Bio Initiates a Phase 2 Clinical Trial of Verekitug (UPB-101) in Severe Asthma and Doses First PatientsJune 19, 2026 | businesswire.comUpstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the ...June 14, 2026 | markets.businessinsider.comUpstream Bio Reports Positive Phase 2 Results for Verekitug in Chronic Rhinosinusitis with Nasal Polyps, Achieving Clinically Meaningful Improvements in Key SymptomsJune 14, 2026 | quiverquant.comQUpstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026June 14, 2026 | globenewswire.comKBRA Assigns Preliminary Ratings to OBX 2026-AHC2 TrustJune 12, 2026 | businesswire.comUpstream Bio Launches $150 Million At-The-Market ProgramJune 11, 2026 | theglobeandmail.comUpstream Bio Shareholders Elect Directors, Ratify 2026 AuditorJune 10, 2026 | tipranks.comUpstream Bio, Inc. (UPB) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptJune 10, 2026 | seekingalpha.comUpstream Bio to Showcase Additional Efficacy Data from the Phase 2 VIBRANT Trial of Verekitug ...June 8, 2026 | enidnews.comEUpstream Bio to Showcase Additional Efficacy Data from the Phase 2 VIBRANT Trial of Verekitug in CRSwNP in Oral Session at EAACI 2026June 8, 2026 | globenewswire.comUpstream Bio to Present at the Goldman Sachs 47th Annual Global Healthcare ConferenceJune 3, 2026 | globenewswire.comUpstream Bio: The Reset Is The Opportunity, Initiating At BuyMay 29, 2026 | seekingalpha.comUpstream Bio Presents New Data from Phase 2 VIBRANT Trial of Verekitug Demonstrating Improvement in Asthma Symptom Control in Participants with CRSwNP and Comorbid Asthma at ...May 18, 2026 | markets.businessinsider.comUpstream Bio Announces Positive Phase 2 VIBRANT Trial Results for Verekitug in Chronic Rhinosinusitis with Nasal Polyps and Comorbid AsthmaMay 18, 2026 | quiverquant.comQUpstream Bio Presents New Data from Phase 2 VIBRANT Trial of Verekitug Demonstrating Improvement in Asthma Symptom Control in Participants with CRSwNP and Comorbid Asthma at the ATS 2026 International ConferenceMay 18, 2026 | globenewswire.comLifeSci Capital Reaffirms Their Buy Rating on Upstream Bio, Inc. (UPB)May 17, 2026 | theglobeandmail.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeUPB, CGON, AVBP, JNJ, and UPB Company DescriptionsArriVent BioPharma NASDAQ:AVBP$33.69 +0.02 (+0.06%) Closing price 07/10/2026 04:00 PM EasternExtended Trading$33.69 0.00 (0.00%) As of 07/10/2026 04:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. to discover and develop antibody drug conjugates (ADCs) with improved activity and safety over single target bivalent ADCs; and Shanghai Allist Pharmaceuticals Co., Ltd. to develop and commercialize Furmonertinib. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.CG Oncology NASDAQ:CGON$75.24 +1.92 (+2.62%) Closing price 07/10/2026 04:00 PM EasternExtended Trading$75.69 +0.45 (+0.60%) As of 07/10/2026 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.Johnson & Johnson NYSE:JNJ$257.17 -1.93 (-0.74%) Closing price 07/10/2026 03:59 PM EasternExtended Trading$256.88 -0.29 (-0.11%) As of 07/10/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.Upstream Bio NASDAQ:UPB$7.53 -0.28 (-3.59%) Closing price 07/10/2026 04:00 PM EasternExtended Trading$7.59 +0.06 (+0.80%) As of 07/10/2026 05:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Upstream Bio, Inc. was incorporated in 2021 and is based in Waltham, Massachusetts.Upstream Bio NASDAQ:UPB$7.53 -0.28 (-3.59%) Closing price 07/10/2026 04:00 PM EasternExtended Trading$7.59 +0.06 (+0.80%) As of 07/10/2026 05:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Upstream Bio, Inc. was incorporated in 2021 and is based in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/06 - 07/10 Delta Air Lines Lives Up to Its Claims: Shares Can Keep Climbing Why WD-40 Is Proving Great Businesses Never Go Out of Style Rocket Lab’s Stock Drop Comes With a Bullish Twist Why "Big Short" Investor Michael Burry Sees Upside in Beaten-Down Sportbook Stocks Microsoft Bets on In-House AI to Cut OpenAI and Anthropic Costs Power Struggle: Wolfspeed Sues Navitas Over AI Chips Pushing the Edge: Super Micro Computer Reboots the AI Landscape Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
